Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
On Wednesday, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and a $4.00 price target on Actinium Pharma (NYSE: ATNM) shares, falling within the broader analyst target range of $2.00 to $9.00. The stock has shown strong momentum with a 30.58% return over the past week. The affirmation follows a recent Key Opinion Leader (KOL) event and pipeline update call held by Actinium. InvestingPro data reveals that 4 analysts have recently revised their earnings expectations downward for the upcoming period. During the event on March 25, the company discussed its clinical advancements, upcoming plans, and feedback from physicians regarding Actinium’s products, Actimab-A and Iomab-ACT.
Dr. Ehab Atallah, a Professor of Medicine at the Medical (TASE:BLWV) College of Wisconsin, was the featured KOL at the event. His insights, along with the detailed updates, were highlighted by Pantginis as a positive sign for the company’s trajectory. The analyst expressed optimism about the combination of supportive KOL feedback, clear clinical plans, and a growing market opportunity for Actinium. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 10.25, indicating robust short-term financial health.
Actinium’s financial position was also a subject of note, with the company expected to have a cash runway extending into mid-2027. This financial stability is seen as a critical factor in supporting Actinium’s progress towards both near-term and long-term goals that could benefit patients and shareholders alike. The company operates with a moderate debt level, with a debt-to-equity ratio of just 0.04, though it’s worth noting that it is not currently profitable, with an EBITDA of -$44.73 million in the last twelve months.
Looking ahead, Pantginis anticipates that 2025 could be a pivotal year for Actinium as it continues to advance its clinical programs. The company is expected to provide numerous updates on its programs in the coming months, which could potentially transform its market standing and deliver significant value to its stakeholders. Investors can access deeper insights and 12 additional ProTips about Actinium’s financial health and market position through InvestingPro, including detailed analysis of its growth prospects and market performance metrics.
In other recent news, Actinium Pharmaceuticals (NYSE:ATNM) has secured a supply of Actinium-225 (Ac-225) from Eckert & Ziegler to advance its clinical trials for cancer treatments. This development is significant as Ac-225 is crucial for Actinium’s targeted radiotherapy treatments, including their lead product, Actimab-A, which is now entering pivotal Phase 2/3 trials for acute myeloid leukemia (AML). Additionally, Actinium reported promising results from a clinical trial of Actimab-A combined with CLAG-M chemotherapy in patients with relapsed or refractory AML, showing a median overall survival of 18.4 months. The trial results, published in the journal Leukemia, revealed a high rate of measurable residual disease negativity, especially in patients with prior Venetoclax therapy.
Furthermore, Actinium has launched a new clinical trial in collaboration with the National Cancer Institute (NCI) to evaluate a triplet combination therapy for newly diagnosed AML patients. This trial aims to assess the safety and efficacy of Actimab-A combined with Venetoclax and ASTX-727. Actinium’s strategic focus is on addressing the needs of over 100,000 AML patients in the U.S. and Europe, with a significant market opportunity for Actimab-A. The company anticipates further clinical trials and preclinical data generation throughout 2025 to establish Actimab-A as a leading targeted radiotherapy. These developments underscore Actinium’s commitment to advancing its targeted radiotherapy platform for AML and potentially other myeloid malignancies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.